Fig 4.

Trypanocidal effect on epimastigotes expressing beta-galactosidase. Epimastigotes were incubated for 72 hours with each compound (named 1 to 6 and indicated on top of each graph) at five concentrations (3.12 to 50 µM). Beta-galactosidase activity was measured, and normalized survival was plotted vs. log concentration. For IC₅₀ calculation of iBET151 and Benznidazole (BZN) (used as positive controls), six concentrations (from 1.56 to 100 µM) were plotted and the curves were fitted using GraphPad Prism 9.0 [non-linear regression: log(inhibitor) vs. response -- Variable slope (four parameters)]. Positive controls gave IC₅₀ values that correlate with those previously reported. BZN is the current drug used for Chagas disease treatment, and iBET151 is a mammalian bromodomain inhibitor that binds TcBDF3.